Seven drugs were recalled in April to protect patients from possible harmful defects associated with the products, the U.S. Food and Drug Administration reported.
Such recalls are voluntary actions carried out by drug makers to remove potentially defective medicines from the market, the FDA said. They may be initiated either by the manufacturer or the FDA.
---
Drug Recalls for April
| Date | Brand Name(s) | Product Description | Reason/Problem | Company Name |
| April 30 | Sagent Pharmaceuticals | Ketorolac Tromethamine Injection | Potential Lack
of Sterility | Sagent Pharmaceuticals |
| April 29 | AmEx Pharmacy | Bevacizumab 1.25mg/0.05mL 31G Injectable | Device & Drug Safety | AmEx Pharmacy |
| April 26 | GSMS Incorporated | Losartan Potassium 25 mg and 100 mg Tablets USP | Device & Drug Safety | Teva Pharmaceuticals USA Inc |
| April 24 | Legacy | Losartan Potassium USP | Unapproved Ingredient | Legacy Pharmaceutical Packaging |
| April 21 | Alvogen | Fentanyl Transdermal System | Device & Drug Safety | Alvogen |
| April 18 | Torrent Pharmaceuticals Limited | Losartan potassium tablets, USP; Losartan potassium and Hydrochlorothiazide tablets, USP | Potential Foreign Material | Torrent Pharmaceuticals Limited |
| April 9 | Platinum 40000 | Aphrodisiac capsules | Unapproved Ingredient | Cape Cod Provisions LLC |
